Abstract
Since the first demonstration by the 4S (Scandinavian Simvastatin Survival Study) trial that treatment of dyslipidemia significantly decreased by 55% the risk of major cardiovascular events (MACE) in patients with type 2 diabetes (T2D) [1], statins have been consecrated as vital drugs for cardiovascular (CV) prevention. Twenty-five year later the original publication of the 4S trial, the American Diabetes Association (ADA) claims that for patients of all ages with diabetes and atherosclerotic cardiovascular disease (ASCVD) or 10-year ASCVD risk >20%, high-intensity statin therapy should be added to lifestyle therapy [2].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
